Rapid Production of Physiologic Dendritic Cells (phDC) for Immunotherapy
Hanlon D, Sobolev O, Han P, Ventura A, Vassall A, Kibbi N, Yurter A, Robinson E, Filler R, Tatsuno K, Edelson RL. Rapid Production of Physiologic Dendritic Cells (phDC) for Immunotherapy. Methods In Molecular Biology 2019, 2097: 173-195. PMID: 31776926, DOI: 10.1007/978-1-0716-0203-4_11.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAntigen-presenting cellsDendritic cellsTumor-associated antigensBlood monocytesDC populationsExtracorporeal photochemotherapyCytokine-derived DCsSource of DCDendritic antigen-presenting cellsHuman peripheral blood mononuclear cellsFunctional antigen-presenting cellsVivo T cell stimulationBlood mononuclear cellsMurine bone marrow precursorsApoptotic tumor cellsT cell stimulationBone marrow precursorsCancer immunotherapyDC differentiationMononuclear cellsIL-4Clinical vaccinationMonocyte activationSupraphysiologic concentrationsNovel Protocol for Generating Physiologic Immunogenic Dendritic Cells.
Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDendritic cellsCellular vaccinesClinical efficacyAnti-tumor T cell immunityVivo anti-tumor responsesMonocyte-derived dendritic cellsTumor cellsSyngeneic mouse tumor modelsImmunogenic dendritic cellsAnti-cancer immunityT cell immunityAnti-tumor responseHuman dendritic cellsT-cell lymphomaAnti-tumor effectsKey mechanistic driversApoptotic tumor cellsMouse tumor modelsCell immunitySafety profileCancer immunotherapyCell lymphomaMouse modelBlood samples